How, if at all, have you incorporated GLP-1 agonists into your fertility-sparing management of patients with EIN or endometrial cancer?

While ultimately not a fertility sparing use, we have begun to use GLP1s in conjunction with dietetic consult, weight loss medicine, and exercise in an attempt to convert patients with medically inoperable endometrial cancer to operability when the only major contraindications is morbid obesity in y...

That is a question that needs to be more clearly defined. We have a project in our endometrial SPORE grant that seeks to answer that question. This project is led by Andrea Hagemann at Washington University. In this project, the effect of weight loss, augmented by GLP1 agonists with weight loss coun...